AGN-199201 for the Treatment of Erythema With Rosacea

Completed · Phase 2

Conditions studied: Rosacea, Erythema

In brief

This study will evaluate the safety and efficacy of 3 doses of AGN-199201 once and twice daily compared to vehicle for the treatment of moderate to severe facial erythema associated with rosacea.

Key facts

Study ID

NCT01735201

Run by

Allergan

People needed

357

Starts

2012-12-01

Expected to finish

2013-06-01

Last updated by the study team

2019-11-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Redness of the skin caused by rosacea

You may not qualify if…

• ≥3 inflammatory lesions
• Laser light-source or other energy based therapy in the last 6 months
• Any prescription or over the counter product for the treatment of acne or rosacea in the last 14 days

Where it is running

• Study site — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.